Salivary Gland Neoplasms × Erlotinib Hydrochloride × Head & Neck × Clear all Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Phase 1 Completed
48 enrolled
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
19 enrolled
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Phase 1 Withdrawn
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Phase 2 Completed
24 enrolled
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase 1/2 Completed
45 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled